59 results on '"Pataje G. S. Prasanna"'
Search Results
2. Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities
- Author
-
C. Norman Coleman, Chandan Guha, Justyna Miszczyk, Pataje G. S. Prasanna, K. Rawojć, and Jeffrey C. Buchsbaum
- Subjects
Male ,Organs at Risk ,Oncology ,Cancer Research ,Lung Neoplasms ,Esophageal Neoplasms ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,law.invention ,Central Nervous System Neoplasms ,0302 clinical medicine ,Randomized controlled trial ,law ,Carcinoma, Non-Small-Cell Lung ,Neoplasms ,Proton Therapy ,Prospective Studies ,Lung ,Gastrointestinal Neoplasms ,Randomized Controlled Trials as Topic ,Radiation ,Brain Neoplasms ,Heart ,Radiotherapy Dosage ,Esophageal cancer ,Progression-Free Survival ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Female ,medicine.medical_specialty ,Breast Neoplasms ,Radiosurgery ,Article ,03 medical and health sciences ,Clinical Trials, Phase II as Topic ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Progression-free survival ,Adverse effect ,Proton therapy ,Photons ,business.industry ,Prostatic Neoplasms ,Radiobiology ,Cancer ,medicine.disease ,Clinical trial ,Radiation therapy ,Quality of Life ,business - Abstract
Despite technological advances in radiotherapy and cancer treatment, patients still experience adverse effects. Proton therapy has emerged as a valuable radiotherapy modality, which can improve treatment outcomes. As normal tissue injury is an important determinant of the outcome, for this review, we analyzed two databases, (i) clinical trials registered in ClinicalTrials.gov and (ii) the literature on proton therapy in PubMed, which shows a steady increase in the number of publications. Most studies in proton therapy registered in the ClinicalTrials.gov with results available are nonrandomized early phase studies, with a relatively small number of patients enrolled. From the larger database of nonrandomized trials, we listed adverse events in specific organ/sites among cancer patients treated with photons and protons to identify critical issues. Present data demonstrate dosimetric advantages of proton therapy with favorable toxicity profiles and forms the basis for comparative randomized prospective trials. Comparative analysis of recently completed three randomized trials for normal tissue toxicities suggest the following: (i) for early stage non-small-cell lung cancer, no meaningful comparison could be made between stereotactic body radiotherapy and stereotactic body proton therapy due to low accrual (NCT01511081), (ii) for locally advanced non-small-cell lung cancer, comparison of intensity-modulated radiotherapy with passive scattering proton therapy (now largely replaced by "spot-scanned" intensity-modulated proton therapy), proton therapy did not provide any benefit in normal tissue toxicity or locoregional failure over photon therapy, and (iii) for locally advanced esophageal cancer proton beam therapy provided a lower total toxicity burden; although it did not improve progression free survival and quality-of-life (NCT01512589). The purpose of this review is to inform the limitations of current trials looking at protons and photons, considering advances in technology, physics, and biology are a continuum and advocate for future trials geared towards accurate precision radiation therapy that needs to be viewed as an iterative process in a defined path towards delivering optimal radiation treatment. A foundational understanding of the radiobiological differences between protons and photons in tumor and normal tissue responses is fundamental to, and necessary for, determining the suitability of a given type of biologically optimized radiation therapy to a patient or a cohort.
- Published
- 2021
3. Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care
- Author
-
Jacek Capala, Bhadrasain Vikram, Pataje G. S. Prasanna, Jeffrey C. Buchsbaum, C. Norman Coleman, Ceferino Obcemea, Julie A Hong, Mansoor M. Ahmed, and Michael Graham Espey
- Subjects
0301 basic medicine ,Big Data ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Big data ,Disease ,Radiation Tolerance ,03 medical and health sciences ,0302 clinical medicine ,Artificial Intelligence ,Neoplasms ,Patient-Centered Care ,Research Support as Topic ,Radiation oncology ,Global health ,Medicine ,Humans ,Medical physics ,Clinical Trials as Topic ,Radiotherapy ,business.industry ,Research ,Cancer ,Radiobiology ,Hyperthermia, Induced ,Neutron Capture Therapy ,medicine.disease ,Health equity ,Radiation therapy ,030104 developmental biology ,Workflow ,Oncology ,Photochemotherapy ,030220 oncology & carcinogenesis ,Commentary ,Radiation Oncology ,Radiopharmaceuticals ,business ,AcademicSubjects/MED00010 ,Relative Biological Effectiveness - Abstract
In a time of rapid advances in science and technology, the opportunities for radiation oncology are undergoing transformational change. The linkage between and understanding of the physical dose and induced biological perturbations are opening entirely new areas of application. The ability to define anatomic extent of disease and the elucidation of the biology of metastases has brought a key role for radiation oncology for treating metastatic disease. That radiation can stimulate and suppress subpopulations of the immune response makes radiation a key participant in cancer immunotherapy. Targeted radiopharmaceutical therapy delivers radiation systemically with radionuclides and carrier molecules selected for their physical, chemical, and biochemical properties. Radiation oncology usage of “big data” and machine learning and artificial intelligence adds the opportunity to markedly change the workflow for clinical practice while physically targeting and adapting radiation fields in real time. Future precision targeting requires multidimensional understanding of the imaging, underlying biology, and anatomical relationship among tissues for radiation as spatial and temporal “focused biology.” Other means of energy delivery are available as are agents that can be activated by radiation with increasing ability to target treatments. With broad applicability of radiation in cancer treatment, radiation therapy is a necessity for effective cancer care, opening a career path for global health serving the medically underserved in geographically isolated populations as a substantial societal contribution addressing health disparities. Understanding risk and mitigation of radiation injury make it an important discipline for and beyond cancer care including energy policy, space exploration, national security, and global partnerships.
- Published
- 2021
4. Therapy-induced senescence: opportunities to improve anti-cancer therapy
- Author
-
Jeffrey Hildesheim, Mansoor M. Ahmed, François Paris, Ana O'Loghlen, Gabriela Riscuta, Dan Xi, Jörg J. Goronzy, Pataje G. S. Prasanna, Daohong Zhou, Judith Campisi, Scott W. Lowe, Sundar Venkatachalam, Guangrong Zheng, David Gius, Clemens A. Schmitt, Paul B. Romesser, C. Norman Coleman, Ann Richmond, Mohamed E Abazeed, Stephen L. Brown, Sandeep Burma, Laura J. Niedernhofer, Jesús Gil, Alexandros G. Georgakilas, David A. Gewirtz, Stephen J. Kron, Marc S. Mendonca, James L. Kirkland, Norman E. Sharpless, Jan M. van Deursen, Deborah Citrin, Mitchell Steven Anscher, Bernardo, Elizabeth, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), University of Florida [Gainesville] (UF), Mayo Clinic [Rochester], Stanford University, University of Chicago, U.S. Food and Drug Administration (FDA), Buck Institute for Research on Aging, Henry Ford Hospital, University of Minnesota [Twin Cities] (UMN), University of Minnesota System, Queen Mary University of London (QMUL), National Technical University of Athens [Athens] (NTUA), Endothelium Radiobiology and Targeting (CRCINA-ÉQUIPE 14), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), University of Texas Southwestern Medical Center [Dallas], Virginia Commonwealth University (VCU), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Vanderbilt University [Nashville], Memorial Sloane Kettering Cancer Center [New York], Indiana University School of Medicine, Indiana University System, University of Texas Health Science Center, and The University of Texas Health Science Center at Houston (UTHealth)
- Subjects
Senescence ,Cancer Research ,Aging ,medicine.medical_treatment ,Oncology and Carcinogenesis ,Radiation Therapy ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,"One-Two Punch" Cancer Therapy ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Senotherapeutics ,Commentaries ,Neoplasms ,Medicine ,Humans ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Cellular Senescence ,030304 developmental biology ,Cancer ,0303 health sciences ,Chemotherapy ,Radiation ,business.industry ,Mechanism (biology) ,Senolytics ,Prevention ,medicine.disease ,Chemotherapy regimen ,Radiation therapy ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Cancer Therapy ,Senescence-Associated Secretory Phenotype ,Senomorphics ,Therapy-Induced Senescence ,AcademicSubjects/MED00010 ,business ,Cell aging ,Biomarkers - Abstract
Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of “one-two punch” cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.
- Published
- 2021
5. FLASH Radiation Therapy: New Technology Plus Biology Required
- Author
-
C. Norman Coleman, Julie A Hong, Michael Graham Espey, Ceferino Obcemea, Jeffrey C. Buchsbaum, Pataje G. S. Prasanna, Jacek Capala, and Mansoor M. Ahmed
- Subjects
Radiation therapy ,Cancer Research ,Flash (photography) ,medicine.medical_specialty ,Radiation ,Oncology ,business.industry ,medicine.medical_treatment ,MEDLINE ,Medicine ,Radiology, Nuclear Medicine and imaging ,Medical physics ,business - Published
- 2021
6. Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
- Author
-
Bhadrasain Vikram, Dale J. Hu, Mansoor M. Ahmed, Ralph R. Weichselbaum, David G. Kirsch, Andrea L. DiCarlo, Silvia C. Formenti, Gayle E. Woloschak, Kathryn D. Held, Chandan Guha, C. Norman Coleman, Arnab Chakravarti, Dörthe Schaue, William H. McBride, Jeffrey C. Buchsbaum, Sunil Krishnan, Pataje G. S. Prasanna, Brian Marples, Wolfgang W. Leitner, Francis A. Cucinotta, Mohammad K. Khan, Shahin Rafii, Julie M. Sullivan, Elad Sharon, and Minesh P. Mehta
- Subjects
Risk ,medicine.medical_specialty ,Radiobiology ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,Pneumonia, Viral ,Biophysics ,MEDLINE ,Radiation Dosage ,Article ,030218 nuclear medicine & medical imaging ,law.invention ,Translational Research, Biomedical ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Radiation oncology ,medicine ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Pandemics ,Clinical Trials as Topic ,Radiation ,business.industry ,COVID-19 ,Radiotherapy Dosage ,Radiation therapy ,030220 oncology & carcinogenesis ,Low Dose Radiation Therapy ,Radiation protection ,business ,Coronavirus Infections - Abstract
The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials of whole-lung low-dose radiation therapy (LDRT; 0.3-1.5 Gy) that are now progressing to phase 2 randomized trials worldwide. This novel but unconventional use of radiation to treat COVID-19 prompted the National Cancer Institute, National Council on Radiation Protection and Measurements and National Institute of Allergy and Infectious Diseases to convene a workshop involving a diverse group of experts in radiation oncology, radiobiology, virology, immunology, radiation protection and public health policy. The workshop was held to discuss the mechanistic underpinnings, rationale, and preclinical and emerging clinical studies, and to develop a general framework for use in clinical studies. Without refuting or endorsing LDRT as a treatment for COVID-19, the purpose of the workshop and this review is to provide guidance to clinicians and researchers who plan to conduct preclinical and clinical studies, given the limited available evidence on its safety and efficacy.
- Published
- 2020
7. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies
- Author
-
Anil K. Rustgi, Terence M. Williams, Geoffrey Liu, Wael El-Rifai, Eric D. Miller, Rosemary Wong, Mansoor M. Ahmed, Bhadrasain Vikram, Michael G. Haddock, Mutlay Sayan, Pataje G. S. Prasanna, Steven H. Lin, Norman Coleman, David H. Ilson, Salma K. Jabbour, Charles A. Kunos, Daniel S. Jamorabo, Jaffer A. Ajani, and Andrew C. Chang
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Esophageal Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Commentaries ,medicine ,Carcinoma ,Humans ,030304 developmental biology ,Curative intent ,0303 health sciences ,Gene targets ,business.industry ,Distant relapse ,Cancer ,Chemoradiotherapy ,Esophageal cancer ,medicine.disease ,Disease control ,Combined Modality Therapy ,030220 oncology & carcinogenesis ,Molecular targets ,Carcinoma, Squamous Cell ,Neoplasm Recurrence, Local ,business - Abstract
Although the development of effective combined chemoradiation regimens for esophageal cancers has resulted in statistically significant survival benefits, the majority of patients treated with curative intent develop locoregional and/or distant relapse. Further improvements in disease control and survival will require the development of individualized therapy based on the knowledge of host and tumor genomics and potentially harnessing the host immune system. Although there are a number of gene targets that are amplified and proteins that are overexpressed in esophageal cancers, attempts to target several of these have not proven successful in unselected patients. Herein, we review our current state of knowledge regarding the molecular pathways implicated in esophageal carcinoma, and the available agents for targeting these pathways that may rationally be combined with standard chemoradiation, with the hope that this commentary will guide future efforts of novel combinations of therapy.
- Published
- 2020
8. Therapeutic proton irradiation results in apoptosis and caspase-3 activation in human peripheral blood lymphocytes
- Author
-
Justyna Miszczyk, Kamila Rawojć, Anna Maria Borkowska, Agnieszka Panek, Jan Swakoń, Aleksander Gałaś, Mansoor M. Ahmed, and Pataje G. S. Prasanna
- Subjects
Cancer Research ,Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2018
9. Accurate, Precision Radiation Medicine: A Meta-Strategy for Impacting Cancer Care, Global Health, and Nuclear Policy and Mitigating Radiation Injury From Necessary Medical Use, Space Exploration, and Potential Terrorism
- Author
-
David A. Pistenmma, Mansoor M. Ahmed, Jeffrey C. Buchsbaum, Jim A. Deye, Bhadrasain Vikram, Manjit Dosanjh, Eric J. Bernhard, Jacques Bernier, Jacek Capala, Ceferino Obcemea, Pataje G. S. Prasanna, and C. Norman Coleman
- Subjects
Cancer Research ,medicine.medical_specialty ,International Cooperation ,Decision Making ,Global Health ,Space exploration ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Radiation oncology ,medicine ,Global health ,Humans ,Organizational Objectives ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Precision Medicine ,Radiation Injuries ,Nuclear energy policy ,Radiation injury ,Societies, Medical ,Radiation ,business.industry ,Health Plan Implementation ,Cancer ,Radiation Exposure ,Space Flight ,Precision medicine ,medicine.disease ,Oncology ,030220 oncology & carcinogenesis ,Terrorism ,Radiation Oncology ,Interdisciplinary Communication ,business - Published
- 2018
10. Medical countermeasures for radiation induced health effects: report of an Interagency Panel Session held at the NASA Human Research Program Investigator's Workshop, 26 January 2017
- Author
-
Carmen I. Rios, Heather N. Meeks, Lanyn P. Taliaferro, Pataje G. S. Prasanna, Lisa S. Carnell, Mary J. Homer, Keith Hoots, Lisa C. Simonsen, and Lynne Wathen
- Subjects
Chronic exposure ,Neutrons ,Medical education ,Radiological and Ultrasound Technology ,Research areas ,United States National Aeronautics and Space Administration ,Radiation induced ,Panel session ,Space Flight ,Space radiation ,United States ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Radiation Protection ,Medical Countermeasures ,030220 oncology & carcinogenesis ,Agency (sociology) ,Humans ,Radiology, Nuclear Medicine and imaging ,Human research ,Psychology ,Radiation Injuries ,Repurposing - Abstract
An Interagency Panel Session organized by the NASA Human Research Program Space Radiation Program Element (SRPE) was held during the NASA Human Research Program (HRP) Investigator’s Workshop (IWS) in Galveston, Texas on January 26, 2017 to identify complementary research areas that will advance the testing and development of medical countermeasures (MCM) in support of radioprotection and radiation mitigation on the ground and in space. There were several areas of common interest identified among the various participating agencies. This report provides a summary of the topics discussed by each agency along with potential areas of intersection for mutual collaboration opportunities. Common goals included repurposing of pharmaceuticals, neutraceuticals for use as radioprotectors and/or mitigators, low-dose/chronic exposure paradigms, late effects post-radiation exposure, mixed-field exposures of gamma-neutron, performance decrements, and methods to determine individual exposure levels.
- Published
- 2019
11. Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway
- Author
-
Kaveh Zakeri, Greg Evans, Bhadrasain Vikram, Jeffrey C. Buchsbaum, Jacek Capala, Pataje G. S. Prasanna, and Deepa Narayanan
- Subjects
Research program ,Targeted radionuclide therapy ,Request for proposal ,03 medical and health sciences ,0302 clinical medicine ,Inventions ,Neoplasms ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Molecular Targeted Therapy ,Small Business ,Small Business Innovation Research ,business.industry ,Cancer ,Small business ,medicine.disease ,Theranostics ,National Cancer Institute (U.S.) ,United States ,Engineering management ,Research Design ,030220 oncology & carcinogenesis ,Radionuclide therapy ,Technology transfer ,business - Abstract
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mandated set-aside programs that provide research funding to for-profit small businesses for the development of innovative technologies and treatments that serve the public good. These two programs have an annual budget of $159 million (in 2017) and serve as the NCI's main engine of innovation for developing and commercializing cancer technologies. In collaboration with the NCI's Radiation Research Program, the NCI SBIR Development Center published in 2015-2017 three separate requests for proposals from small businesses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer. TRT combines a cytotoxic radioactive isotope with a molecularly targeted agent to produce an anticancer therapy capable of treating local or systemic disease. This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them.
- Published
- 2019
12. A Bleak Future for Evidence-Based Radiation Oncology: An Analysis of Phase III Clinical Trials Performed During 2000-2019
- Author
-
Zvi Symon, H.J. Mamon, Yaacov Richard Lawrence, Uri Amit, A. Shtern, Galia Jacobson, Amanda J. Walker, Pataje G. S. Prasanna, Ben Boursi, David Goldstein, and Adam P. Dicker
- Subjects
Cancer Research ,medicine.medical_specialty ,Radiation ,Evidence-based practice ,Oncology ,business.industry ,Radiation oncology ,Medicine ,Phases of clinical research ,Radiology, Nuclear Medicine and imaging ,Medical physics ,business - Published
- 2020
13. UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES BIODOSIMETRY AND RADIOLOGICAL/NUCLEAR MEDICAL COUNTERMEASURE PROGRAMS
- Author
-
Lynne Wathen, Francesca Macchiarini, Carmen Rios, Chad Hrdina, Mary J. Homer, Bert W. Maidment, Andrea L. DiCarlo-Cohen, Robert E. Raulli, Brian R. Moyer, Pataje G. S. Prasanna, and John L. Esker
- Subjects
Paper ,medicine.medical_specialty ,National security ,MEDLINE ,Disaster Planning ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Radiation Monitoring ,medicine ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Program Development ,Radiometry ,Human services ,Radiation ,Operationalization ,Radiological and Ultrasound Technology ,business.industry ,Public health ,Public Health, Environmental and Occupational Health ,General Medicine ,medicine.disease ,United States ,Interinstitutional Relations ,Countermeasure ,Models, Organizational ,030220 oncology & carcinogenesis ,Radiological weapon ,Preparedness ,Terrorism ,United States Dept. of Health and Human Services ,Public Health ,Medical emergency ,Business ,Emergencies ,Radioactive Hazard Release - Abstract
The United States Department of Health and Human Services (HHS) is fully committed to the development of medical countermeasures to address national security threats from chemical, biological, radiological, and nuclear agents. Through the Public Health Emergency Medical Countermeasures Enterprise, HHS has launched and managed a multi-agency, comprehensive effort to develop and operationalize medical countermeasures. Within HHS, development of medical countermeasures includes the National Institutes of Health (NIH), (led by the National Institute of Allergy and Infectious Diseases), the Office of the Assistant Secretary of Preparedness and Response/Biomedical Advanced Research and Development Authority (BARDA); with the Division of Medical Countermeasure Strategy and Requirements, the Centers for Disease Control and Prevention, and the Food and Drug Administration as primary partners in this endeavor. This paper describes various programs and coordinating efforts of BARDA and NIH for the development of medical countermeasures for radiological and nuclear threats.
- Published
- 2016
14. Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials
- Author
-
Michael Baumann, Henning Willers, Mark W. Dewhirst, David G. Kirsch, J. Martin Brown, Geoff S. Higgins, Pataje G. S. Prasanna, C. Norman Coleman, Mansoor M. Ahmed, and Eric J. Bernhard
- Subjects
0301 basic medicine ,Drug ,Oncology ,Radiation-Sensitizing Agents ,Cancer Research ,medicine.medical_specialty ,media_common.quotation_subject ,medicine.medical_treatment ,Drug Evaluation, Preclinical ,Antineoplastic Agents ,Bioinformatics ,Radiation Tolerance ,Article ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Cancer stem cell ,In vivo ,Cell Line, Tumor ,Neoplasms ,Internal medicine ,medicine ,Animals ,Humans ,Molecular Targeted Therapy ,Clonogenic assay ,media_common ,Mechanism (biology) ,business.industry ,Reproducibility of Results ,Cancer ,medicine.disease ,Xenograft Model Antitumor Assays ,Clinical trial ,Radiation therapy ,Disease Models, Animal ,030104 developmental biology ,030220 oncology & carcinogenesis ,Neoplastic Stem Cells ,business ,HeLa Cells - Abstract
There is an urgent need to improve reproducibility and translatability of preclinical data to fully exploit opportunities for molecular therapeutics involving radiation and radiochemotherapy. For in vitro research, the clonogenic assay remains the current state-of-the-art of preclinical assays, whereas newer moderate and high-throughput assays offer the potential for rapid initial screening. Studies of radiation response modification by molecularly targeted agents can be improved using more physiologic 3D culture models. Elucidating effects on the cancer stem cells (CSC, and CSC-like) and developing biomarkers for defining targets and measuring responses are also important. In vivo studies are necessary to confirm in vitro findings, further define mechanism of action, and address immunomodulation and treatment-induced modification of the microenvironment. Newer in vivo models include genetically engineered and patient-derived xenograft mouse models and spontaneously occurring cancers in domesticated animals. Selection of appropriate endpoints is important for in vivo studies; for example, regrowth delay measures bulk tumor killing, whereas local tumor control assesses effects on CSCs. The reliability of individual assays requires standardization of procedures and cross-laboratory validation. Radiation modifiers must be tested as part of clinical standard of care, which includes radiochemotherapy for most tumors. Radiation models are compatible with but also differ from those used for drug screening. Furthermore, the mechanism of a drug as a chemotherapeutic agent may be different from its interaction with radiation and/or radiochemotherapy. This provides an opportunity to expand the use of molecular-targeted agents. Clin Cancer Res; 22(13); 3138–47. ©2016 AACR.
- Published
- 2016
15. Effects of 60 MeV Protons and 250 kV X-Rays on Cell Viability
- Author
-
Aleksander Gałaś, Justyna Miszczyk, Agnieszka Panek, Pataje G. S. Prasanna, Jan Swakoń, K. Rawojć, and Marzena Rydygier
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Materials science ,030220 oncology & carcinogenesis ,Radiochemistry ,General Physics and Astronomy ,Viability assay - Abstract
Particle radiotherapy such as the one using proton beams, provides a successful treatment approach in many cancer types. However, the cellular and molecular mechanisms by which proton irradiation induces cell death, particularly in a human peripheral blood lymphocyte model has not been examined in detail. Comparative studies of the biological effects, such as cell death, of particle therapy versus conventional X-rays treatment are of utmost importance. Here, we compared the viability of human peripheral blood lymphocyte following in vitro irradiation with protons (therapeutic 60 MeV proton beam) and photon beam (250 kV, X-rays), by applying separate doses within the range of 0.3-4.0 Gy. Cell viability was assessed 1 and 4 h after irradiation with protons and X-rays by the FITC-Annexin V labelling procedure (Apoptotic & Necrotic & Healthy Cells Quantification Kit, Biotium). Results showed that irradiation with both radiation types reduced the number of viable cells in a dose-dependent manner, as assessed as a function of the duration of post-irradiation time. Protons proved more fatal to the cells treated than X-ray photons. This demonstrates a difference in cell viability after irradiation with protons and photons in a human peripheral blood lymphocyte model.
- Published
- 2016
16. High-throughput sample processing and sample management; the functional evolution of classical cytogenetic assay towards automation
- Author
-
Pataje G. S. Prasanna, Adarsh Ramakumar, and Uma Subramanian
- Subjects
Automation, Laboratory ,Chromosome Aberrations ,business.industry ,Computer science ,Health, Toxicology and Mutagenesis ,Sample processing ,Bioinformatics ,Automation ,High-Throughput Screening Assays ,Reliability engineering ,Management information systems ,Functional evolution ,Biodosimetry ,Cytogenetic Analysis ,Laboratory automation ,Genetics ,Chromosomes, Human ,Humans ,Radiometry ,business ,Quality assurance - Abstract
High-throughput individual diagnostic dose assessment is essential for medical management of radiation-exposed subjects after a mass casualty. Cytogenetic assays such as the Dicentric Chromosome Assay (DCA) are recognized as the gold standard by international regulatory authorities. DCA is a multi-step and multi-day bioassay. DCA, as described in the IAEA manual, can be used to assess dose up to 4-6 weeks post-exposure quite accurately but throughput is still a major issue and automation is very essential. The throughput is limited, both in terms of sample preparation as well as analysis of chromosome aberrations. Thus, there is a need to design and develop novel solutions that could utilize extensive laboratory automation for sample preparation, and bioinformatics approaches for chromosome-aberration analysis to overcome throughput issues. We have transitioned the bench-based cytogenetic DCA to a coherent process performing high-throughput automated biodosimetry for individual dose assessment ensuring quality control (QC) and quality assurance (QA) aspects in accordance with international harmonized protocols. A Laboratory Information Management System (LIMS) is designed, implemented and adapted to manage increased sample processing capacity, develop and maintain standard operating procedures (SOP) for robotic instruments, avoid data transcription errors during processing, and automate analysis of chromosome-aberrations using an image analysis platform. Our efforts described in this paper intend to bridge the current technological gaps and enhance the potential application of DCA for a dose-based stratification of subjects following a mass casualty. This paper describes one such potential integrated automated laboratory system and functional evolution of the classical DCA towards increasing critically needed throughput.
- Published
- 2015
17. Development of Novel Radiosensitizers through the National Cancer Institute's Small Business Innovation Research Program
- Author
-
Jeffrey C. Buchsbaum, Pataje G. S. Prasanna, Kaveh Zakeri, Deepa Narayanan, and Bhadrasain Vikram
- Subjects
Radiation-Sensitizing Agents ,medicine.medical_specialty ,Standard of care ,Biophysics ,Request for proposal ,Improved survival ,Article ,030218 nuclear medicine & medical imaging ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Drug Discovery ,Overall survival ,medicine ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Small Business ,Small Business Innovation Research ,Radiation ,business.industry ,Research ,Cancer ,medicine.disease ,National Cancer Institute (U.S.) ,United States ,Clinical trial ,030220 oncology & carcinogenesis ,business - Abstract
While radiosensitizing chemotherapy has improved survival for several types of cancer, current chemoradiation regimens remain ineffective for many patients and have substantial toxicities. Given the strong need for the development of novel radiosensitizers to further improve patient outcomes, the Radiation Research Program (RRP) and the Small Business Innovation Research (SBIR) in the National Cancer Institute (NCI) issued a Request for Proposals (RFP) through the NCI SBIR Development Center's contracts pathway. We sought to determine the research outcomes for the NCI SBIR Development Center's funded proposals for the development of radiosensitizers. We identified SBIR-funded contracts and grants for the development of radiosensitizers from 2009 to 2018 using the National Institutes of Health (NIH) Reporter database. Research outcomes of the NCI SBIR Development Center-funded proposals were determined using a comprehensive internet search. We searched PubMed, clinicaltrials.gov, company websites and google.com for research articles, abstracts and posters, clinical trials, press releases and other news, related to progress in the development of funded radiosensitizers. To protect the intellectual property of the investigators and small businesses, all information obtained and reported is publicly available. The SBIR Program has funded four contracts and 11 grants for the development of novel radiosensitizers. Two companies have received phase IIb bridge awards. Overall, 50% of companies (6/12) have successfully advanced their investigational drugs into prospective clinical trials in cancer patients, and all but one company are investigating their drug in combination with radiation therapy as described in the NCI SBIR Development Center proposal. To date, only one company has initiated a randomized trial of standard of care with or without their radiosensitizer. In conclusion, the NCI SBIR Development Center has funded the development of novel radiosensitizers leading to clinical trials of novel drugs in combination with radiation therapy. Continued follow-up is needed to determine if any of these novel radiosensitizers produce improved tumor control and/or overall survival.
- Published
- 2020
18. Radiation Biomarkers: Can Small Businesses Drive Accurate Radiation Precision Medicine?
- Author
-
Deepa Narayanan, Bhadrasain Vikram, C. Norman Coleman, Pataje G. S. Prasanna, Kehui Zhang, and Amir Rahbar
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Biophysics ,MEDLINE ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Radiation sensitivity ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Precision Medicine ,Radiation ,Radiotherapy ,business.industry ,Commerce ,Cancer ,Precision medicine ,medicine.disease ,Clinical trial ,Radiation therapy ,Treatment interruption ,030220 oncology & carcinogenesis ,business ,Biomarkers - Abstract
Radiation therapy is an essential component of cancer treatment. Currently, tumor control and normal tissue complication probabilities derived from a general patient population guide radiation treatment. Its outcome could be improved if radiation biomarkers could be incorporated into approaches to treatment. A substantial number of cancer patients suffer from side effects of radiation therapy. These side effects can result in treatment interruption. Such unplanned treatment interruptions not only jeopardize anticancer treatment efficacy but also result in poor post-treatment quality-of-life. To develop and translate radiation biomarkers for clinical use, NCI's Radiation Research Program, in collaboration with the Small Business Innovation Research Development Center, funded four small businesses through the request for proposals after peer review during 2015-2019. Here, we summarize publicly available information on intellectual property rights, the status of development, ongoing clinical trials, success in obtaining financing and regulatory approval. An analysis of publicly available information indicates all four companies have completed phase I of SBIR funding and advanced to further development, validation and clinical trials with phase II SBIR funding. These biomarkers are: 1. A panel of genomic biomarkers of radiation response to predict toxicity and radioimmune response (MiraDx Inc., Los Angeles, CA); 2. A multiplex assay for single nucleotide polymorphism (SNP) biomarkers of radiation sensitivity to identify a subset of prostate cancer patients for which radiotherapy is contraindicated (L2 Diagnostics, New Haven, CT); 3. A cell-free DNA assay in blood to measure tissue damage shortly after radiation exposure (DiaCarta Inc., Richmond, CA); and 4. A metabolomic/lipidomic assay to predict late effects that adversely affect quality-of-life among patients treated with radiation for prostate cancer (Shuttle Pharmaceuticals, Rockville, MD). This work also provides a bird's eye view of the process of developing radiation biomarkers for use in radiation oncology clinics, some of the challenges and future directions.
- Published
- 2020
19. Decreasing the Toxicity of Radiation Therapy: Radioprotectors and Radiomitigators Being Developed by the National Cancer Institute Through Small Business Innovation Research Contracts
- Author
-
C. Norman Coleman, Pataje G. S. Prasanna, Greg Evans, Bhadrasain Vikram, Kaveh Zakeri, and Deepa Narayanan
- Subjects
Cancer Research ,Research program ,medicine.medical_specialty ,Financing, Government ,medicine.medical_treatment ,Request for proposal ,Contracts ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Radiation Protection ,Inventions ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Small Business ,Small Business Innovation Research ,Technology, Radiologic ,Radiation ,INVESTIGATIONAL AGENTS ,business.industry ,National Cancer Institute (U.S.) ,United States ,Radiation therapy ,Clinical trial ,Clinical Practice ,Oncology ,030220 oncology & carcinogenesis ,business - Abstract
Purpose The use of radioprotectors and radiomitigators could improve the therapeutic index of radiation therapy. With the intention of accelerating translation of radiation-effect modulators (radioprotectors and mitigators), the Radiation Research Program and SBIR (Small Business Innovation Research) Development Center within the National Cancer Institute issued 4 Requests for Proposals (RFPs) from 2010 to 2013. Twelve SBIR contract awards in total were made in response to the 4 RFPs from September 2011 through September 2014. Here, we provide an update on the status of SBIR contract projects for the development of radiation-effect modulators. Methods and Materials To assess the status of research and development efforts under the 4 RFPs on radiation-effect modulators, we searched PubMed for research articles, google.com for published abstracts, clinicaltrials.gov for ongoing or completed clinical trials, and company websites for press releases and other news. All information obtained and reported here is publicly available and thus protects the intellectual property of the investigators and companies. Results Of the 12 SBIR projects funded, 5 (42%) transitioned successfully from phase 1 to phase 2 SBIR funding, and among the Fast-Track contracts, this rate was 100% (3 of 3). The Internet search identified 3 abstracts and 6 publications related to the aims of the SBIR contracts. One-third of the companies (4 of 12) have successfully launched a total of 8 clinical trials to demonstrate the safety and efficacy of their investigational agents. Two drugs are in clinical trials for their indication as a radioprotector, and 2 drugs are under evaluation for their anticancer properties (an immunomodulator and a small molecule inhibitor). Conclusions The National Cancer Institute's SBIR has provided pivotal funding to small businesses for the development of radioprotectors and radiomitigators, which resulted in multiple early-phase clinical trials. Longer follow-up is needed to determine the full impact of these novel therapeutics that enter clinical practice.
- Published
- 2018
20. Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches-Meeting Viewpoint
- Author
-
Silvia C. Formenti, Radhe Mohan, Molykutty J. Aryankalayil, Pataje G. S. Prasanna, Stephen M. Seltzer, Søren M. Bentzen, Beverly A. Teicher, Jeffrey C. Buchsbaum, Joel E. Tepper, David Raben, Gary D. Kao, Kevin M. Prise, David G. Kirsch, Bhadrasain Vikram, Fei-Fei Liu, Deborah Citrin, Daphne A. Haas-Kogan, Mansoor M. Ahmed, James B. Mitchell, Dee Dee K. Smart, Jacek Capala, Dudley T. Goodhead, Marc S. Mendonca, Ceferino Obcemea, Quynh-Thu Le, C. Norman Coleman, and Iris Eke
- Subjects
Cancer Research ,medicine.medical_specialty ,Particle therapy ,business.industry ,Quantitative Biology::Tissues and Organs ,medicine.medical_treatment ,Physics::Medical Physics ,030218 nuclear medicine & medical imaging ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,SDG 3 - Good Health and Well-being ,030220 oncology & carcinogenesis ,medicine ,Journal Article ,Medical physics ,business - Abstract
The ability to physically target radiotherapy using image-guidance is continually improving with photons and particle therapy that include protons and heavier ions such as carbon. The unit of dose deposited is the gray (Gy); however, particle therapies produce different patterns of ionizations, and
- Published
- 2018
21. Do protons and X-rays induce cell-killing in human peripheral blood lymphocytes by different mechanisms?
- Author
-
Aleksander Gałaś, Agnieszka Panek, Jan Swakoń, K. Rawojć, Pataje G. S. Prasanna, Justyna Miszczyk, Anna M. Borkowska, and Mansoor M. Ahmed
- Subjects
0301 basic medicine ,Programmed cell death ,Necrosis ,medicine.medical_treatment ,Lymphocyte ,R895-920 ,Apoptosis ,Cell-killing modes ,Article ,Medical physics. Medical radiology. Nuclear medicine ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Photon therapy ,medicine ,Radiology, Nuclear Medicine and imaging ,RC254-282 ,Radiotherapy ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Proton biology ,Human peripheral blood lymphocytes ,Proton therapy ,Radiation therapy ,030104 developmental biology ,Cell killing ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,medicine.symptom ,business ,Ex vivo - Abstract
Purpose Significant progress has been made in the technological and physical aspects of dose delivery and distribution in proton therapy. However, mode of cell killing induced by protons is less understood in comparison with X-rays. The purpose of this study is to see if there is any difference in the mode of cell-killing, induced by protons and X-rays in an ex vivo human peripheral blood lymphocyte (HPBL) model. Materials and methods HPBL were irradiated with 60 MeV proton beam or 250-kVp X-rays in the dose range of 0.3–4.0 Gy. Frequency of apoptotic and necrotic cells was determined by the Fluorescein (FITC)-Annexin V labelling procedure, 1 and 4 h after irradiation. Chip-based DNA Ladder Assay was used to confirm radiation-induced apoptosis and necrosis. Chip-based DNA Ladder Assay was used to confirm radiation-induced apoptosis. Results Ex vivo irradiation of HPBL with proton beams of 60 MeV or 250 kVp X-rays resulted in apoptotic as well as necrotic modes of cell-killing, which were evident at both 1 and 4 h after irradiation in the whole dose and time range. Generally, our results indicated that protons cause relatively higher yields of cell death that appears to be necrosis compared to X-rays. The analysis also demonstrates that radiation type and dose play a critical role in mode of cell-killing. Conclusion Obtained results suggest that X-rays and protons induce cell-killing by different modes. Such differences in cell-killing modes may have implications on the potential of a given therapeutic modality to cause immune modulation via programmed cell death (X-rays) or necrotic cell death (proton therapy). These studies point towards exploring for gene expression biomarkers related necrosis or apoptosis to predict immune response after proton therapy.
- Published
- 2018
22. Current Status of Radiation Oncology Research funded through the National Cancer Institute’s Small Business Innovation Research Program
- Author
-
Greg Evans, Bhadrasain Vikram, C.N. Coleman, Jacek Capala, Jeffrey C. Buchsbaum, M. Weingarten, Deepa Narayanan, Pataje G. S. Prasanna, and Kaveh Zakeri
- Subjects
Cancer Research ,Medical education ,Radiation ,Oncology ,business.industry ,Radiation oncology ,Medicine ,Cancer ,Radiology, Nuclear Medicine and imaging ,Current (fluid) ,business ,medicine.disease ,Small Business Innovation Research - Published
- 2018
23. Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016
- Author
-
Michael L. Freeman, Amanda J. Walker, Deborah Citrin, Ruth C. Wilkins, Benjamin Movsas, Thomas A. Wynn, Jeffrey C. Buchsbaum, Iris Eke, Pataje G. S. Prasanna, Mitchell S. Anscher, Eric P. Cohen, C. Norman Coleman, Molykutty J. Arankalayil, Mansoor M. Ahmed, Marc S. Mendonca, and Mary Helen Barcellos-Hoff
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Research program ,Pathology ,Pulmonary Fibrosis ,Radiation induced fibrosis ,Treatment outcome ,Biophysics ,Translational research ,Critical research ,Medical and Health Sciences ,Article ,Vaccine Related ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Radiation oncology ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Oncology & Carcinogenesis ,Cancer ,Evidence-Based Medicine ,Radiation ,Radiotherapy ,business.industry ,Prevention ,Evidence-based medicine ,Biological Sciences ,United States ,National Cancer Institute (U.S.) ,Radiation Pneumonitis ,Clinical trial ,Treatment Outcome ,030104 developmental biology ,030220 oncology & carcinogenesis ,Physical Sciences ,business - Abstract
A workshop entitled “Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate” (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval.
- Published
- 2017
24. Radiation-induced brain damage, impact of Michael Robbins’ work and the need for predictive biomarkers
- Author
-
Helen B. Stone, C. Norman Coleman, Bhadrasain Vikram, Pataje G. S. Prasanna, Mansoor M. Ahmed, and Minesh P. Mehta
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Context (language use) ,Radiation induced ,Brain damage ,Radiation Dosage ,Radiosurgery ,Quality of life ,Internal medicine ,medicine ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Predictive biomarker ,Chemotherapy ,Radiological and Ultrasound Technology ,Brain Neoplasms ,business.industry ,Brain ,Cognition ,Surgery ,Radiation therapy ,Brain Injuries ,Radiation Oncology ,medicine.symptom ,business ,Biomarkers - Abstract
To review the literature on radiation-induced normal tissue injury in the context of treatment of primary and metastatic brain tumors with a focus on Michael Robbins' work on mechanisms of injury and approaches to mitigation, and also to identify other potential opportunities to improve treatment outcome and quality of life (QOL).Brain tumors remain a significant challenge for patients, their families, the physicians treating them, and researchers seeking more effective treatments. Current treatment of brain tumors involves combinations of radiotherapy with surgery, chemotherapy, and molecularly targeted agents. As patient survival improves with advances in treatment there is an increasing concern for the cognitive deficits that may become apparent months or years after treatment some of which are related to radiation-induced brain damage. One area of Michael Robbins' research was unraveling the mechanisms of radiation-induced cognitive deficits, which formed the basis for the development of some mitigators of radiation injury. Extrapolating from this, new opportunities to identify and develop putative predictive biomarkers of radiation-induced brain damage can be explored.Predictive biomarkers of radiation-induced brain injury may enable stratifying patients for customization of treatment and thus aid in improving the QOL and possibly prolonging survival. Here we discuss the challenges involved in leveraging recent advances in radiation-specific biomarker research and translating them to radiotherapy, which for the foreseeable future is likely to remain a cornerstone of the treatment of brain tumors.
- Published
- 2014
25. Current Insights in Radiation Combination Therapies: Influence of Omics and Novel Targeted Agents in Defining New Concepts in Radiation Biology and Clinical Radiation Oncology
- Author
-
Mansoor M. Ahmed, C. Norman Coleman, Amogh Narendra, Pataje G. S. Prasanna, and Sunil Krishnan
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Radiobiology ,business.industry ,Chemoradiotherapy ,Omics ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Neoplasms ,Radiation oncology ,Radiation Oncology ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,business - Published
- 2016
26. Biological dosimetry by the triage dicentric chromosome assay – Further validation of international networking
- Author
-
Y. Suto, Ursula Oestreicher, Leonora Marro, Mitsuaki A. Yoshida, Horst Romm, Ruth C. Wilkins, and Pataje G. S. Prasanna
- Subjects
Radiation ,business.industry ,Mass Casualty ,Triage ,Article ,Peripheral blood ,Dicentric chromosome ,Biodosimetry ,Medicine ,Dosimetry ,Metaphase spread ,Nuclear medicine ,business ,Dose rate ,Instrumentation - Abstract
Biological dosimetry is an essential tool for estimating radiation doses received to personnel when physical dosimetry is not available or inadequate. The current preferred biodosimetry method is based on the measurement of radiation-specific dicentric chromosomes in exposed individuals' peripheral blood lymphocytes. However, this method is labour-, time- and expertise-demanding. Consequently, for mass casualty applications, strategies have been developed to increase its throughput. One such strategy is to develop validated cytogenetic biodosimetry laboratory networks, both national and international. In a previous study, the dicentric chromosome assay (DCA) was validated in our cytogenetic biodosimetry network involving five geographically dispersed laboratories. A complementary strategy to further enhance the throughput of the DCA among inter-laboratory networks is to use a triage DCA where dose assessments are made by truncating the labour-demanding and time-consuming metaphase-spread analysis to 20 to 50 metaphase spreads instead of routine 500 to 1000 metaphase spread analysis. Our laboratory network also validated this triage DCA, however, these dose estimates were made using calibration curves generated in each laboratory from the blood samples irradiated in a single laboratory. In an emergency situation, dose estimates made using pre-existing calibration curves which may vary according to radiation type and dose rate and therefore influence the assessed dose. Here, we analyze the effect of using a pre-existing calibration curve on assessed dose among our network laboratories. The dose estimates were made by analyzing 1000 metaphase spreads as well as triage quality scoring and compared to actual physical doses applied to the samples for validation. The dose estimates in the laboratory partners were in good agreement with the applied physical doses and determined to be adequate for guidance in the treatment of acute radiation syndrome.
- Published
- 2011
27. Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15–18 October 2017; Cancun, Mexico
- Author
-
Yaacov Richard Lawrence, Ricky A. Sharma, C. Norman Coleman, Pataje G. S. Prasanna, Sunil J. Advani, Mansoor M. Ahmed, Bhadrasain Vikram, Richard A. Amos, and Kelly C. Falls
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Research program ,Radiation ,business.industry ,Biophysics ,Normal tissue ,Article ,Scientific evidence ,03 medical and health sciences ,Preclinical research ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Radiation oncology ,Medicine ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Professional association ,business ,Repurposing - Abstract
The National Cancer Institute’s (NCI) Radiation Research Program (RRP) is endeavoring to increase the relevance of preclinical research to improve outcomes of radiation therapy for cancer patients. These efforts include conducting symposia, workshops and educational sessions at annual meetings of professional societies, including the American Association of Physicists in Medicine, American Society of Radiation Oncology, Radiation Research Society (RRS), Radiosurgery Society, Society of Nuclear Medicine and Molecular Imaging, Society for Immunotherapy of Cancer and the American Association of Immunology. A symposium entitled “Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities” was conducted by the NCI’s RRP during the 63rd Annual Meeting of the RRS on October 16, 2017 in Cancun, Mexico. In this symposium, discussions were held to address the challenges in developing radiation-drug combinations, optimal approaches with scientific evidence to replace standard-of-care, approaches to reduce normal tissue toxicities and enhance post-treatment quality-of-life and recent advances in antibody-drug conjugates. The symposium included two broad overview talks followed by two talks illustrating examples of radiation-drug combinations under development. The overview talks identified the essential preclinical infrastructure necessary to accelerate progress in the development of evidence and important challenges in the translation of drug combinations to the clinic from the laboratory. Also addressed, in the example talks (in light of the suggested guidelines and identified challenges), were the development and translation of novel antibody drug conjugates as well as repurposing of drugs to improve efficacy and reduce normal tissue toxicities. Participation among a cross section of clinicians, scientists and scholars-in-training alike who work in this focused area highlighted the importance of continued discussions to identify and address complex challenges in this emerging area in radiation oncology.
- Published
- 2018
28. TRIAGE DOSE ASSESSMENT FOR PARTIAL-BODY EXPOSURE: DICENTRIC ANALYSIS
- Author
-
Pataje G. S. Prasanna, Maria Moroni, and Terry C. Pellmar
- Subjects
Oncology ,medicine.medical_specialty ,Epidemiology ,Health, Toxicology and Mutagenesis ,Signs and symptoms ,Biology ,Radiation Dosage ,Sensitivity and Specificity ,Whole-Body Counting ,Article ,Dicentric chromosome ,Biodosimetry ,Internal medicine ,Dose prediction ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiometry ,business.industry ,Reproducibility of Results ,Mass Casualty ,Environmental Exposure ,Triage ,Radiological weapon ,Dose assessment ,Body Burden ,Biological Assay ,Nuclear medicine ,business - Abstract
Partial-body biodosimetry is likely to be required after a radiological or nuclear exposure. Clinical signs and symptoms, distribution of dicentrics in circulating blood cells, organ-specific biomarkers, and physical signals in teeth and fingernails all can provide indications of non-homogeneous exposures. Organ specific biomarkers may provide early warning regarding physiological systems at risk after radiation injury. Use of a combination of markers and symptoms will be needed for clinical insights for therapeutic approaches. Analysis of dicentrics, a marker specific for radiation injury, is the "gold standard" of biodosimetry and can reveal partial-body exposures. Automation of sample processing for dicentric analysis can increase throughput with customization of off-the-shelf technologies for cytogenetic sample processing and information management. Automated analysis of the metaphase spreads is currently limited, but improvements are in development. The efforts described here bridge the technological gaps to allow the use of dicentric chromosome assay (DCA) for risk-based stratification of mass casualties. This article summarizes current knowledge on partial-body cytogenetic dose assessment, synthesizing information leading to the proposal of an approach to triage dose prediction in radiation mass casualties that is based on equivalent whole-body doses under partial-body exposure conditions and assesses the validity of using this model. An initial screening using only 20 metaphase spreads per subject can confirm irradiation above 2 Gy. A subsequent increase to 50 metaphases improves dose determination to allow risk stratification for clinical triage. Metaphases evaluated for inhomogeneous distribution of dicentrics can reveal partial-body exposures. The authors tested the validity of this approach in an in vitro model that simulates partial-body irradiation by mixing irradiated and un-irradiated lymphocytes in various proportions. Preliminary results support the notion that this approach will be effective under a range of conditions including some partial-body exposures, but may have limitations with low doses or small proportions of irradiated parts of the body. These studies address an important problem in the diagnosis of partial-body irradiation and dose assessment in mass casualties and propose a solution. However, additional work is needed to fully develop and validate the application of DCA to partial-body exposures.
- Published
- 2010
29. Genistein Protects Against Biomarkers of Delayed Lung Sequelae in Mice Surviving High-Dose Total Body Irradiation
- Author
-
Michael R. Landauer, Thomas A. Davis, Pataje G. S. Prasanna, Michal Barshishat-Kupper, Steven R. Mog, Elizabeth A McCart, and Regina M. Day
- Subjects
Pathology ,medicine.medical_specialty ,Health, Toxicology and Mutagenesis ,Genistein ,Radiation-Protective Agents ,Lung injury ,Radiation Dosage ,Article ,Andrology ,Mice ,chemistry.chemical_compound ,Subcutaneous injection ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Receptor ,Lung ,Pneumonitis ,Respiratory Distress Syndrome ,Radiation ,Dose-Response Relationship, Drug ,business.industry ,Dose-Response Relationship, Radiation ,Total body irradiation ,medicine.disease ,Survival Analysis ,Mice, Inbred C57BL ,Survival Rate ,medicine.anatomical_structure ,chemistry ,Micronucleus test ,Cytokines ,Female ,business ,Biomarkers ,Whole-Body Irradiation - Abstract
The effects of genistein on 30-day survival and delayed lung injury were examined in C57BL/6J female mice. A single subcutaneous injection of vehicle (PEG-400) or genistein (200 mg/kg) was administered 24 h before total body irradiation (7.75 Gy (60)Co, 0.6 Gy/min). Experimental groups were: No treatment + Sham (NC), Vehicle + Sham (VC), Genistein + Sham (GC), Radiation only (NR), Vehicle + Radiation (VR), Genistein + Radiation (GR). Thirty-day survivals after 7.75 Gy were: NR 23%, VR 53%, and GR 92%, indicating significant protection from acute radiation injury by genistein. Genistein also mitigated radiation-induced weight loss on days 13-28 postirradiation. First generation lung fibroblasts were analyzed for micronuclei 24 h postirradiation. Fibroblasts from the lungs of GR-treated mice had significantly reduced micronuclei compared with NR mice. Collagen deposition was examined by histochemical staining. At 90 days postirradiation one half of the untreated and vehicle irradiated mice had focal distributions of small collagen-rich plaques in the lungs, whereas all of the genistein-treated animals had morphologically normal lungs. Radiation reduced the expression of COX-2, transforming growth factor-beta receptor (TGFbetaR) I and II at 90 days after irradiation. Genistein prevented the reduction in TGFbetaRI. However, by 180 days postirradiation, these proteins normalized in all groups. These results demonstrate that genistein protects against acute radiation-induced mortality in female mice and that GR-treated mice have reduced lung damage compared to NR or VR. These data suggest that genistein is protective against a range of radiation injuries.
- Published
- 2008
30. Amylase and blood cell-count hematological radiation-injury biomarkers in a rhesus monkey radiation model—use of multiparameter and integrated biological dosimetry
- Author
-
Marcy B. Grace, C. A. Salter, Natalia I. Ossetrova, William E. Jackson, William F. Blakely, Pataje G. S. Prasanna, David J Sandgren, G.L. Manglapus, Ira H. Levine, and G.D. Ledney
- Subjects
Physics ,medicine.medical_specialty ,Radiation ,biology ,business.industry ,Lymphocyte ,Gastroenterology ,Blood cell ,medicine.anatomical_structure ,Biodosimetry ,Internal medicine ,Blood plasma ,medicine ,biology.protein ,Dosimetry ,Amylase ,Irradiation ,Radiation protection ,business ,Nuclear medicine ,Instrumentation - Abstract
Effective medical management of suspected radiation exposure incidents requires the recording of dynamic medical data (clinical signs and symptoms), biological assessments of radiation exposure, and physical dosimetry in order to provide diagnostic information to the treating physician and dose assessment for personnel radiation protection records. The need to rapidly assess radiation dose in mass-casualty and population-monitoring scenarios prompted an evaluation of suitable biomarkers that can provide early diagnostic information after exposure. We investigated the utility of serum amylase and hematological blood-cell count biomarkers to provide early assessment of severe radiation exposures in a non-human primate model (i.e., rhesus macaques; n = 8 ) exposed to whole-body radiation of Co 60 -gamma rays (6.5 Gy, 40 cGy min - 1 ). Serum amylase activity was significantly elevated ( 12.3 ± 3.27 - and 2.6 ± 0.058 -fold of day zero samples) at 1 and 2-days, respectively, after radiation. Lymphocyte cell counts decreased ( ⩽ 15 % of day zero samples) 1 and 2 days after radiation exposure. Neutrophil cell counts increased at day one by 1.9 ( ± 0.38 ) -fold compared with levels before irradiation. The ratios of neutrophil to lymphocyte cell counts increased by 13 ( ± 2.66 ) - and 4.23 ( ± 0.95 ) -fold at 1 and 2 days, respectively, after irradiation. These results demonstrate that increases in serum amylase activity along with decreases of lymphocyte counts, increases in neutrophil cell counts, and increases in the ratio of neutrophil to lymphocyte counts 1 day after irradiation can provide enhanced early triage discrimination of individuals with severe radiation exposure and injury. Use of the biodosimetry assessment tool (BAT) application is encouraged to permit dynamic recording of medical data in the management of a suspected radiological casualty.
- Published
- 2007
31. Radioprotectors and Radiomitigators for Improving Radiation Therapy: The Small Business Innovation Research (SBIR) Gateway for Accelerating Clinical Translation
- Author
-
Deepa Narayanan, C. Norman Coleman, Mansoor M. Ahmed, Eric J. Bernhard, Kory Hallett, Pataje G. S. Prasanna, Bhadrasain Vikram, Michael Weingarten, and Gregory R. D. Evans
- Subjects
Research program ,medicine.medical_specialty ,medicine.medical_treatment ,Biophysics ,Article ,Quality of life (healthcare) ,Radiation Protection ,Neoplasms ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Small Business ,Small Business Innovation Research ,Megakaryocyte Progenitor Cells ,Government ,Radiation ,Radiotherapy ,business.industry ,Thrombin ,Genetic Therapy ,Venture capital ,Small business ,Genistein ,Peptide Fragments ,Radiation therapy ,Toll-Like Receptor 5 ,Drug development ,Immunology ,Quality of Life ,business - Abstract
Although radiation therapy is an important cancer treatment modality, patients may experience adverse effects. The use of a radiation-effect modulator may help improve the outcome and health-related quality of life (HRQOL) of patients undergoing radiation therapy either by enhancing tumor cell killing or by protecting normal tissues. Historically, the successful translation of radiation-effect modulators to the clinic has been hindered due to the lack of focused collaboration between academia, pharmaceutical companies and the clinic, along with limited availability of support for such ventures. The U.S. Government has been developing medical countermeasures against accidental and intentional radiation exposures to mitigate the risk and/or severity of acute radiation syndrome (ARS) and the delayed effects of acute radiation exposures (DEARE), and there is now a drug development pipeline established. Some of these medical countermeasures could potentially be repurposed for improving the outcome of radiation therapy and HRQOL of cancer patients. With the objective of developing radiation-effect modulators to improve radiotherapy, the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI), supported by the Radiation Research Program (RRP), provided funding to companies from 2011 to 2014 through the SBIR contracts mechanism. Although radiation-effect modulators collectively refer to radioprotectors, radiomitigators and radiosensitizers, the focus of this article is on radioprotection and mitigation of radiation injury. This specific SBIR contract opportunity strengthened existing partnerships and facilitated new collaborations between academia and industry. In this commentary, we assess the impact of this funding opportunity, outline the review process, highlight the organ/site-specific disease needs in the clinic for the development of radiation-effect modulators, provide a general understanding of a framework for gathering preclinical and clinical evidence to obtain regulatory approval and provide a basis for broader venture capital needs and support from pharmaceutical companies to fully capitalize on the advances made thus far in this field.
- Published
- 2015
32. Evaluation of the DNA damage induced by 60 MeV proton irradiation by cytogenetic and molecular methods
- Author
-
W.M. Kwiatek, Aleksander Gałaś, Agnieszka Panek, Justyna Miszczyk, Jan Swakoń, Pataje G. S. Prasanna, K. Rawojć, Mansoor M. Ahmed, and L. Malinowski
- Subjects
Oncology ,Proton ,Radiology Nuclear Medicine and imaging ,DNA damage ,Chemistry ,Radiochemistry ,Radiology, Nuclear Medicine and imaging ,Hematology ,Irradiation - Published
- 2016
33. Nucleic Acid Molecular Biomarkers for Diagnostic Biodosimetry Applications: Use of the Fluorogenic 5′-Nuclease Polymerase Chain Reaction Assay
- Author
-
Christine J. C. Hamel, Joseph T. Nelson, Nestor E. Escalada, Zachary D. Hornby, Alexandra C. Miller, Jason Lukas, Pataje G. S. Prasanna, William F. Blakely, and Lei Luo
- Subjects
Nuclease ,Nucleic acid quantitation ,biology ,Chemistry ,Public Health, Environmental and Occupational Health ,General Medicine ,Molecular biology ,Reverse transcriptase ,law.invention ,Biodosimetry ,law ,Complementary DNA ,Nucleic acid ,biology.protein ,Multiplex ,Polymerase chain reaction - Abstract
A reliable, relatively easy method for diagnostic assessment of radiation exposure is needed to support the triage of radiation casualties and medical treatment decisions in military defense operations. Our strategy is toidentify radiation-responsive DNA mutations and gene expression targets that can be analyzed using polymerase chain reaction (PCR) assays and an existing fluorescence-based nucleic acid analysis system designed for forward-deployable laboratory applications. Using an in vitro model system of human peripheral blood lymphocytes, we identified a candidate nucleic acid biomarker (i.e., gene expression target) that is responsive to ionizing radiation. In this report, we describe our preliminary Haras gene expression findings. A dose-dependent elevation in Haras gene expression levels was demonstrated using Northern-blot analysis 17 hours after exposure to a 250-kVp dose of X-rays (25-100 cGy, 1 Gy/minute); c-Haras expression levels at 100 cGy were ninefold higher than those of controls. An alternative protocol to quantify the Haras cDNA target, using the rapid, real-time reverse transcriptase fluorogenic 5'-nuclease PCR assay, is described, along with a preliminary characterization of the dynamic range for detection. Our research shows that the analysis of multitarget nucleic acid biomarkers, using the multiplex fluorogenic 5'-nuclease PCR assay, has beneficial applications in radiation epidemiology, radiation therapy, and biodosimetry.
- Published
- 2002
34. Potential Late Health Effects of Depleted Uranium and Tungsten Used in Armor-Piercing Munitions: Comparison of Neoplastic Transformation and Genotoxicity with the Known Carcinogen Nickel
- Author
-
Michael Stewart, Pataje G. S. Prasanna, Jiaquan Xu, Alexandra C. Miller, and Natalie Page
- Subjects
Neoplasms, Radiation-Induced ,Chemistry ,Public Health, Environmental and Occupational Health ,Poison control ,Sister chromatid exchange ,General Medicine ,equipment and supplies ,medicine.disease_cause ,Tungsten ,Toxicology ,Nickel ,In vivo ,Micronucleus test ,Carcinogens ,Cancer research ,medicine ,Humans ,Uranium ,Wounds, Gunshot ,Neoplastic transformation ,Carcinogenesis ,Genotoxicity ,Carcinogen - Abstract
Limited data exist to permit an accurate assessment of risks for carcinogenesis and mutagenesis from embedded fragments or inhaled particulates of depleted uranium (DU). Ongoing studies have been designed to provide information about the carcinogenic potential of DU using in vitro and in vivo assessments of morphological transformation as well as cytogenetic, mutagenic, and oncogenic effects. For comparison, we also examined tungsten alloys used in military projectiles and the known carcinogen nickel. Quantitative and qualitative in vitro transformation studies were done to assess the carcinogenic potential of radiation and chemical hazards. Using a human osteosarcoma cell model, we demonstrated that soluble and insoluble DU compounds can transform cells to the tumorigenic phenotype, as characterized by morphological, biochemical, and oncogenic changes consistent with tumor cell behavior. Tungsten alloys and nickel were also shown to be neoplastic transforming agents, although at a frequency less than that of DU. Sister chromatid exchange, micronuclei, and alkaline filter elution assays showed DU and tungsten alloys were genotoxic. Exposure to a nontoxic, nontransforming dose of DU induced a small but statistically significant increase in the number of dicentrics formed in cells. These results suggest that long-term exposure to DU or tungsten alloys could be critical to the development of neoplastic disease in humans and that additional studies are needed.
- Published
- 2002
35. Response of human lymphocytes to proton radiation of 60 MeV compared to 250 kV X-rays by the cytokinesis-block micronucleus assay
- Author
-
Pataje G. S. Prasanna, Jan Swakoń, K. Rawojć, Agnieszka Panek, Marzena Rydygier, and Justyna Miszczyk
- Subjects
Adult ,Male ,Proliferation index ,DNA damage ,Binucleated cells ,Radiation ,Radiation Dosage ,Humans ,Radiology, Nuclear Medicine and imaging ,Irradiation ,Lymphocytes ,Cells, Cultured ,Cell Proliferation ,Cytokinesis ,Cell Nucleus ,Micronucleus Tests ,business.industry ,Chemistry ,Hematology ,Middle Aged ,In vitro ,Oncology ,Micronucleus test ,Cancer research ,Female ,Protons ,Micronucleus ,Nuclear medicine ,business ,DNA Damage - Abstract
Particle radiotherapy such as protons provides a new promising treatment modality to cancer. However, studies on its efficacy and risks are relatively sparse. Using the cytokinesis-blocked micronucleus assay, we characterized response of human peripheral blood lymphocytes, obtained from health donors irradiated in vitro in the dose range: 0-4. 0 Gy, to therapeutic proton radiation of 60 MeV from AIC-144 isochronous cyclotron, by studying nuclear division index and DNA damage and compared them with X-rays. Peripheral blood lymphocytes show decreased ability to proliferate with increasing radiation doses for both radiation types, however, in contrast to X-rays, irradiation with protons resulted in a higher proliferation index at lower doses of 0.75 and 1.0 Gy. Protons are more effective in producing MN at doses above 1.75 Gy compared to X-rays. Dose-response curves for micronucleus incidence can be best described by a cubic model for protons, while for X-rays the response was linear. The differences in the energy spectrum and intracellular distribution of energy between radiation types are also apparent at the intracellular distribution of cytogenetic damage as seen by the distribution of various numbers of micronuclei in binucleated cells. Our studies, although preliminary, further contribute to the understanding of the mechanistic differences in the response of HPBL in terms of cellular proliferation and cytogenetic damage induced by protons and X-rays as well as intra-cellular distribution of energy and thus radiobiological effectiveness.
- Published
- 2014
36. Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development
- Author
-
Pataje G. S. Prasanna, Michael Fenech, Stephen S. Yoo, Gary J. Kelloff, Alla Shapiro, Ann R. Kennedy, Timothy J. Jorgensen, John D. Boice, C. Norman Coleman, Tom C.-C. Hu, Brian R. Moyer, and Marcy B. Grace
- Subjects
medicine.medical_specialty ,Neoplasms, Radiation-Induced ,Radiation induced ,Radiation-Protective Agents ,Radiation Dosage ,Risk Assessment ,Article ,Ionizing radiation ,Radiation Protection ,Biodosimetry ,Medicine ,Humans ,Medical physics ,Intensive care medicine ,Radiometry ,Waste Management and Disposal ,business.industry ,Public Health, Environmental and Occupational Health ,Acute Radiation Syndrome ,Cancer ,General Medicine ,medicine.disease ,Drug development ,Radiological weapon ,Drug Design ,Radiation-induced cancer ,business ,Radioactive Hazard Release - Abstract
The United States radiation medical countermeasures (MCM) programme for radiological and nuclear incidents has been focusing on developing mitigators for the acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE), and biodosimetry technologies to provide radiation dose assessments for guiding treatment. Because a nuclear accident or terrorist incident could potentially expose a large number of people to low to moderate doses of ionising radiation, and thus increase their excess lifetime cancer risk, there is an interest in developing mitigators for this purpose. This article discusses the current status, issues, and challenges regarding development of mitigators against radiation-induced cancers. The challenges of developing mitigators for ARS include: the long latency between exposure and cancer manifestation, limitations of animal models, potential side effects of the mitigator itself, potential need for long-term use, the complexity of human trials to demonstrate effectiveness, and statistical power constraints for measuring health risks (and reduction of health risks after mitigation) following relatively low radiation doses (
- Published
- 2014
37. Premature chromosome condensation in human resting peripheral blood lymphocytes without mitogen stimulation for chromosome aberration analysis using specific whole chromosome DNA hybridization probes
- Author
-
Rupak, Pathak and Pataje G S, Prasanna
- Subjects
Microscopy, Fluorescence ,Chromosomes, Human ,Humans ,Cell Separation ,Lymphocytes ,Chromatin Assembly and Disassembly ,DNA Probes ,Cells, Cultured ,Chromosome Painting ,Fluorescent Dyes - Abstract
We have previously described a unique, simple, and rapid method for inducing premature chromosome condensation (PCC) in "resting" human peripheral blood lymphocytes (HPBLs) without mitogen stimulation and an approach for studying numerical changes and/or structural aberrations involving a specific pair of human chromosomes. The current protocol incorporates improvements that provide better PCC, incorporates a high-throughput automated sample preparation unit and metaphase harvester to minimize manual labor and improve quality, and supports simultaneous painting of multiple sets of human autosomes in interphase nuclei. To induce PCC, isolated HPBLs are incubated at 37 °C in cell culture medium supplemented with a phosphatase inhibitor (okadaic acid or calyculin A), adenosine triphosphate, and p34(cdc2)/cyclin B kinase (an essential component of mitosis-promoting factor) for a short period of time. PCC spreads are prepared on glass slides using a humidity- and temperature-controlled chamber (an auto-spreader) after a brief hypotonic treatment and fixation. Aberrations involving specific sets of painted human chromosome are analyzed using fluorescence microscopy. Each of the normal (undamaged) painted homologous chromosome pairs displays two fluorescent spots, whereas cells with numerical and/or structural aberration involving specific painted chromosome sets show deviation in the number of fluorescent spots. The identification and quantification of aberration involving specific chromosomes in interphase nuclei have important applications in radiobiology, toxicology, radiation therapeutics, and cancer research.
- Published
- 2014
38. Premature Chromosome Condensation in Human Resting Peripheral Blood Lymphocytes Without Mitogen Stimulation for Chromosome Aberration Analysis Using Specific Whole Chromosome DNA Hybridization Probes
- Author
-
Rupak Pathak and Pataje G. S. Prasanna
- Subjects
Autosome ,Premature chromosome condensation ,Homologous chromosome ,Fluorescence microscope ,Chromosome ,Interphase ,Biology ,Metaphase ,Molecular biology ,Chromosome aberration - Abstract
We have previously described a unique, simple, and rapid method for inducing premature chromosome condensation (PCC) in "resting" human peripheral blood lymphocytes (HPBLs) without mitogen stimulation and an approach for studying numerical changes and/or structural aberrations involving a specific pair of human chromosomes. The current protocol incorporates improvements that provide better PCC, incorporates a high-throughput automated sample preparation unit and metaphase harvester to minimize manual labor and improve quality, and supports simultaneous painting of multiple sets of human autosomes in interphase nuclei. To induce PCC, isolated HPBLs are incubated at 37 °C in cell culture medium supplemented with a phosphatase inhibitor (okadaic acid or calyculin A), adenosine triphosphate, and p34(cdc2)/cyclin B kinase (an essential component of mitosis-promoting factor) for a short period of time. PCC spreads are prepared on glass slides using a humidity- and temperature-controlled chamber (an auto-spreader) after a brief hypotonic treatment and fixation. Aberrations involving specific sets of painted human chromosome are analyzed using fluorescence microscopy. Each of the normal (undamaged) painted homologous chromosome pairs displays two fluorescent spots, whereas cells with numerical and/or structural aberration involving specific painted chromosome sets show deviation in the number of fluorescent spots. The identification and quantification of aberration involving specific chromosomes in interphase nuclei have important applications in radiobiology, toxicology, radiation therapeutics, and cancer research.
- Published
- 2014
39. Quantitative plasmid mixture analysis using the fluorogenic 5?-nuclease polymerase chain reaction assay
- Author
-
Wendy Pogozelski, Christine J. C. Hamel, Pataje G. S. Prasanna, William F. Blakely, Richard S. Lofts, and Alison E. Director-Myska
- Subjects
Deoxyribonucleases ,Base Sequence ,Epidemiology ,Health, Toxicology and Mutagenesis ,Inverse polymerase chain reaction ,Templates, Genetic ,In Vitro Techniques ,Biology ,Polymerase Chain Reaction ,Molecular biology ,Real-time polymerase chain reaction ,Primer dimer ,Multiplex polymerase chain reaction ,TaqMan ,Humans ,Digital polymerase chain reaction ,Multiplex ,Applications of PCR ,Genetics (clinical) ,DNA Primers ,Fluorescent Dyes ,Plasmids - Abstract
The fluorogenic 5'-nuclease polymerase chain reaction (PCR) assay has been shown to be useful for quantifying a given DNA target in a sample. Here we show how an existing PCR protocol can be amended for quantification by incorporating distinctive dual-labeled, sequence-specific oligonucleotide probes and resulting in a two- to threefold broader and more reliable dynamic range than that of conventional end-point analysis of PCR products. Moreover, we show a multiplex situation in which two targets, one normal and one mutated, can be amplified and quantified simultaneously and in the same reaction tube. Use of this novel approach for quantitative PCR applications eliminates the need for post-PCR processing and has clinical- and research-based diagnostic applications, particularly for measuring levels of mutations in a mixture.
- Published
- 2001
40. Induction of premature chromosome condensation by a phosphatase inhibitor and a protein kinase in unstimulated human peripheral blood lymphocytes: a simple and rapid technique to study chromosome aberrations using specific whole-chromosome DNA hybridization probes for biological dosimetry
- Author
-
William F. Blakely, Pataje G. S. Prasanna, and Nestor D. Escalada
- Subjects
Time Factors ,Health, Toxicology and Mutagenesis ,Lymphocyte ,Cyclin B ,Chromosome Painting ,CDC2 Protein Kinase ,Okadaic Acid ,Phosphoprotein Phosphatases ,Genetics ,medicine ,Chromosomes, Human ,Humans ,Lymphocytes ,Radiometry ,Mitosis ,Chromosome Aberrations ,Cyclin-dependent kinase 1 ,Dose-Response Relationship, Drug ,biology ,medicine.diagnostic_test ,Mutagenicity Tests ,Kinase ,Chromosome ,Dose-Response Relationship, Radiation ,Molecular biology ,Cyclin-Dependent Kinases ,medicine.anatomical_structure ,Premature chromosome condensation ,biology.protein ,Mitogens ,CDC28 Protein Kinase, S cerevisiae ,Fluorescence in situ hybridization - Abstract
We developed a simple and rapid method to study chromosome aberrations involving specific chromosomes using unstimulated human peripheral blood lymphocytes (HPBL). Premature chromosome condensation (PCC) was induced by incubating unstimulated HPBL in the presence of okadaic acid (OA, a phosphatase inhibitor), adenosine triphosphate (ATP), and p34(cdc2)/cyclin B kinase [an essential component of mitosis-promoting factor (MPF)], which eliminated the need for fusion with mitotic cells. OA concentration and duration of incubation for PCC induction was optimized using mitogen-stimulated HPBL; a final concentration of 0.75 microM incubated for 3 h was optimum, resulting in approximately 20% PCC yield. In unstimulated HPBL, PCC was induced by the addition of p34(cdc2)/cyclin B kinase at concentrations as low as 5 units/ml to a cell culture medium containing OA. Increases in the concentration of p34(cdc2)/cyclin B kinase from 5 to 50 units/ml resulted in a concentration-dependent increase in PCC yield (30% to 42%). We demonstrate that this technique of inducing PCC in unstimulated HPBL is suitable for studying radiation-induced aberrations involving a specific chromosome (chromosome 1) after 24 h repair using a whole-chromosome in situ hybridization probe and chromosome painting. Cells with aberrant chromosome number 1 are characterized with more than two chromosome spots. The frequency of cells with aberrant chromosome 1 increased with 60Co gamma-radiation doses in the region 0-7.5 Gy. The observed dose-effect relationship for the percentage of cells with aberrant chromosome 1 (Y) was explained by using both a linear [Y=(2.77+/-0.230)D+0.90+/-0.431, r(2)=0.966] and a nonlinear power [Y=(5.70+/-0.46)D((0.61+/-0.05)), r(2)=0.9901) model. This technique can be applied to biological dosimetry of radiation exposures involving uniform whole-body low linear energy transfer (LET) exposures.
- Published
- 2000
41. In Situ Detection of a PCR-Synthesized Human Pancentromeric DNA Hybridization Probe by Color Pigment Immunostaining: Application for Dicentric Assay Automation
- Author
-
Joginder Nath, William F. Blakely, Harry Loats, Mark D. Pyle, Christopher J. Kolanko, and Pataje G. S. Prasanna
- Subjects
Male ,In situ ,Histology ,Centromere ,Color ,Biology ,Azure Stains ,Polymerase Chain Reaction ,Chromosome aberration ,Chromosome Painting ,law.invention ,Automation ,Dicentric chromosome ,chemistry.chemical_compound ,Tandem repeat ,law ,Chromosomes, Human ,Humans ,Lymphocytes ,In Situ Hybridization ,Metaphase ,Polymerase chain reaction ,Chromosome Aberrations ,Microscopy ,Hybridization probe ,DNA–DNA hybridization ,Pigments, Biological ,Templates, Genetic ,General Medicine ,Immunohistochemistry ,Molecular biology ,Medical Laboratory Technology ,chemistry ,Tandem Repeat Sequences ,DNA Probes ,DNA - Abstract
We report a low cost and efficient method for synthesizing a human pancentromeric DNA probe by the polymerase chain reaction (PRC) and an optimized protocol for in situ detection using color pigment immunostaining. The DNA template used in the PCR was a 2.4 kb insert containing human alphoid repeated sequences of pancentromeric DNA subcloned into pUC9 (Miller et al. 1988) and the primers hybridized to internal sequences of the 172 bp consensus tandem repeat associated with human centromeres. PCR was performed in the presence of biotin-11-dUTP, and the product was used for in situ hybridization to detect the pancentromeric region of human chromosomes in metaphase spreads. Detection of pancentromeric probe was achieved by immunoenzymatic color pigment painting to yield a permanent image detected at high resolution by bright field microscopy. The ability to synthesize the centromeric probe rapidly and to detect it with color pigment immunostaining will lead to enhanced identification and eventually to automation of various chromosome aberration assays.
- Published
- 2000
42. Assessment of biodosimetry methods for a mass-casualty radiological incident: medical response and management considerations
- Author
-
Marcy B. Grace, Rodney L. Wallace, Lynne Wathen, John F. Koerner, Pataje G. S. Prasanna, Julie M. Sullivan, and C. Norman Coleman
- Subjects
medicine.medical_specialty ,Epidemiology ,Neutrophils ,Health, Toxicology and Mutagenesis ,Biophysical Phenomena ,Article ,Biodosimetry ,Medicine ,Chromosomes, Human ,Humans ,Mass Casualty Incidents ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Lymphocytes ,Time point ,Radiometry ,Point of care ,Cytokinesis ,Micronucleus Tests ,business.industry ,Mass Casualty ,Hematology ,Triage ,Mass-casualty incident ,MicroRNAs ,Preparedness ,Radiological weapon ,Cytogenetic Analysis ,Biological Assay ,business ,Nuclear medicine ,Radioactive Hazard Release ,Transcriptome ,Biomarkers ,DNA Damage - Abstract
Following a mass-casualty nuclear disaster, effective medical triage has the potential to save tens of thousands of lives. In order to best use the available scarce resources, there is an urgent need for biodosimetry tools to determine an individual's radiation dose. Initial triage for radiation exposure will include location during the incident, symptoms, and physical examination. Stepwise triage will include point of care assessment of less than or greater than 2 Gy, followed by secondary assessment, possibly with high throughput screening, to further define an individual's dose. Given the multisystem nature of radiation injury, it is unlikely that any single biodosimetry assay can be used as a standalone tool to meet the surge in capacity with the timeliness and accuracy needed. As part of the national preparedness and planning for a nuclear or radiological incident, the authors reviewed the primary literature to determine the capabilities and limitations of a number of biodosimetry assays currently available or under development for use in the initial and secondary triage of patients. Understanding the requirements from a response standpoint and the capability and logistics for the various assays will help inform future biodosimetry technology development and acquisition. Factors considered include: type of sample required, dose detection limit, time interval when the assay is feasible biologically, time for sample preparation and analysis, ease of use, logistical requirements, potential throughput, point-of-care capability, and the ability to support patient diagnosis and treatment within a therapeutically relevant time point.
- Published
- 2013
43. Biological Dosimetry Using Human Interphase Peripheral Blood Lymphocytes
- Author
-
Nestor D. Escalada, William F. Blakely, Pataje G. S. Prasanna, Christine J. C. Hamel, and Keife L. Duffy
- Subjects
medicine.medical_specialty ,Pathology ,medicine.diagnostic_test ,business.industry ,Public Health, Environmental and Occupational Health ,Cytogenetics ,Chromosome ,Chromosomal translocation ,General Medicine ,Molecular biology ,Biodosimetry ,Premature chromosome condensation ,medicine ,Interphase ,business ,Mitosis ,Fluorescence in situ hybridization - Abstract
Conventional metaphase-spread chromosome-aberration-based biodosimetry techniques for radiation dose assessment, although robust, are laborious and time consuming. The molecular cytogenetic laboratory of the Armed Forces Radiobiology Research Institute is developing simple and rapid interphase-based cytological assays that will be applicable to a broad range of radiation exposure scenarios. These assays include analysis of chromosome aberrations (premature chromosome condensation-fluorescence in situ hybridization assay) and mitochondrial DNA mutations (mtDNA4977 deletion assay) using resting human peripheral blood lymphocytes. The dose-effect relationship for radiation-induced aberrations involving chromosome 1 after 24 hours of repair at 37 degrees C in resting human peripheral blood lymphocytes was studied using fluorescence in situ hybridization after chemical induction of premature chromosome condensation as previously explained. In the present study, we examined whether gamma irradiation in the range of 0 to 7.5 Gy induces a dose-dependent increase in aberrations manifested as "excess spots." The number of excess spots per cell, reflecting aberrations involving chromosome 1, increased from 0.035 at 0.5 Gy to 0.236 at 7.5 Gy. This observed dose-effect relationship was fit with a nonlinear power model. This technique may be extended to the study of radiation-induced translocations in interphase cells for retrospective dose reconstruction. With a recently developed in situ polymerase chain reaction method to detect and quantify mtDNA deletion in interphase cells after radiation exposure in cultured human peripheral blood lymphocytes, 90% to 95% of cells are analyzable. We discuss the potential use of the mtDNA deletion assay in biological dosimetry applications. Interphase-based cytological assays may eliminate some inherent problems associated with metaphase-spread-based assays. These problems involve (1) the limited number of analyzable cells containing chromosome aberrations, which is due to various factors including radiation-induced cell death and delay in cell cycle progression into mitosis, and (2) the requirements for radiation cytogenetics expertise and tedious labor to manually score chromosome aberrations.
- Published
- 2002
44. Biological dosimetry by the triage dicentric chromosome assay: potential implications for treatment of acute radiation syndrome in radiological mass casualties
- Author
-
Terry C. Pellmar, Horst Romm, Pataje G. S. Prasanna, Akio A. Awa, Mitsuaki A. Yoshida, Mark S. Jenkins, Patricia K. Lillis-Hearne, Ruth C. Wilkins, C. Norman Coleman, Gordon K. Livingston, and Ursula Oestreicher
- Subjects
medicine.medical_specialty ,Radiobiology ,Biophysics ,Dicentric chromosome ,Biodosimetry ,medicine ,Dosimetry ,Chromosomes, Human ,Humans ,Mass Casualty Incidents ,Radiology, Nuclear Medicine and imaging ,Radiometry ,Metaphase ,Radiation ,Dose-Response Relationship, Drug ,business.industry ,Acute Radiation Syndrome ,Triage ,Mass-casualty incident ,Radiological weapon ,Calibration ,Radiology ,business ,Nuclear medicine ,Radioactive Hazard Release - Abstract
Biological dosimetry is an essential tool for estimating radiation dose. The dicentric chromosome assay (DCA) is currently the tool of choice. Because the assay is labor-intensive and time-consuming, strategies are needed to increase throughput for use in radiation mass casualty incidents. One such strategy is to truncate metaphase spread analysis for triage dose estimates by scoring 50 or fewer metaphases, compared to a routine analysis of 500 to 1000 metaphases, and to increase throughput using a large group of scorers in a biodosimetry network. Previously, the National Institutes for Allergies and Infectious Diseases (NIAID) and the Armed Forces Radiobiology Research Institute (AFRRI) sponsored a double-blinded interlaboratory comparison among five established international cytogenetic biodosimetry laboratories to determine the variability in calibration curves and in dose measurements in unknown, irradiated samples. In the present study, we further analyzed the published data from this previous study to investigate how the number of metaphase spreads influences dose prediction accuracy and how this information could be of value in the triage and management of people at risk for the acute radiation syndrome (ARS). Although, as expected, accuracy decreased with lower numbers of metaphase spreads analyzed, predicted doses by the laboratories were in good agreement and were judged to be adequate to guide diagnosis and treatment of ARS. These results demonstrate that for rapid triage, a network of cytogenetic biodosimetry laboratories can accurately assess doses even with a lower number of scored metaphases.
- Published
- 2011
45. Biodosimety Assessment Tool: A Post-Exposure Software Application for Management of Radiation Accidents
- Author
-
Pataje G. S. Prasanna, Ronald E. Goans, Ira H. Levine, Aimee L. Hawley, Richard G. Greenhill, Marcy B. Grace, William E. Jackson, William F. Blakely, and Rebecca C. Sine
- Subjects
medicine.medical_specialty ,Diagnostic information ,Post exposure ,business.industry ,Public health ,Public Health, Environmental and Occupational Health ,General Medicine ,medicine.disease ,Surgery ,Software ,Biodosimetry ,Health care ,medicine ,Dosimetry ,Medical emergency ,business ,Radiation Accidents - Abstract
The Biodosimetry Assessment Tool software application under development will equip health care providers with diagnostic information (clinical signs and symptoms, physical dosimetry, etc.) germane to the management of human radiation casualties. Designed primarily for prompt use after a radiation incident, the user-friendly program facilitates collection, integration, and archiving of data obtained from exposed persons. Data collected in templates are compared with established radiation dose responses obtained from the literature to provide multiparameter dose assessments. The program archives clinical information (e.g., extent of contamination, wounds, infection, etc.) useful for casualty management, displays relevant diagnostic information in a concise format, and can be used to manage both military and civilian radiation accidents. In addition, monitoring of diagnostic information of individuals using this program could potentially minimize the severity of psychological casualties by making a marked impact on the way that both radiation casualties and the worried well view their exposure, dose, and future risk for the development of disease.
- Published
- 2001
46. Synopsis of Partial-Body Radiation Diagnostic Biomarkers and Medical Management of Radiation Injury Workshop
- Author
-
John P. Chute, David Lloyd, Ronald E. Goans, Natalia I. Ossetrova, Ludy C. H. W. Lutgens, Eduardo G. Yukihara, Andrzej Wojcik, Alexander Romanyukha, Patricia K. Lillis-Hearne, Pataje G. S. Prasanna, Daniel J. Weisdorf, Jean Marc Bertho, Eric P. Cohen, Julie D. Saba, Viktor Meineke, Marcy B. Grace, William F. Blakely, and Terry C. Pellmar
- Subjects
medicine.medical_specialty ,Pathology ,Radiation ,Extramural ,business.industry ,Biophysics ,MEDLINE ,Signs and symptoms ,Article ,Biodosimetry ,Homogeneous ,medicine ,Diagnostic biomarker ,Radiology, Nuclear Medicine and imaging ,Medical physics ,business ,Radiation injury - Abstract
Radiation exposures from accidents, nuclear detonations or terrorist incidents are unlikely to be homogeneous; however, current biodosimetric approaches are developed and validated primarily in whole-body irradiation models. A workshop was held at the Armed Forces Radiobiology Research Institute in May 2008 to draw attention to the need for partial-body biodosimetry, to discuss current knowledge, and to identify the gaps to be filled. A panel of international experts and the workshop attendees discussed the requirements and concepts for a path forward. This report addresses eight key areas identified by the Workshop Program Committee for future focus: (1) improved cytogenetics, (2) clinical signs and symptoms, (3) cutaneous bioindicators, (4) organ-specific biomarkers, (5) biophysical markers of dose, (6) integrated diagnostic approaches, (7) confounding factors, and (8) requirements for post-event medical follow-up. For each area, the status, advantages and limitations of existing approaches and suggestions for new directions are presented.
- Published
- 2010
47. Differential radio-sensitivities of human chromosomes 1 and 2 in one donor in interphase- and metaphase-spreads after 60Co γ-irradiation
- Author
-
Adarsh Ramakumar, Uma Subramanian, Rupak Pathak, and Pataje G. S. Prasanna
- Subjects
Pathology ,medicine.medical_specialty ,Colcemid ,Cell division ,Somatic cell ,Chromosome ,Biology ,Cell biology ,chemistry.chemical_compound ,chemistry ,Radiology Nuclear Medicine and imaging ,Premature chromosome condensation ,medicine ,Radiology, Nuclear Medicine and imaging ,Interphase ,Mitosis ,Metaphase ,Research Article - Abstract
Background Radiation-induced chromosome aberrations lead to a plethora of detrimental effects at cellular level. Chromosome aberrations provide broad spectrum of information ranging from probability of malignant transformation to assessment of absorbed dose. Studies mapping differences in radiation sensitivities between human chromosomes are seldom undertaken. Consequently, health risk assessment based on radio-sensitivities of individual chromosomes may be erroneous. Our efforts in this article, attempt to demonstrate differences in radio-sensitivities of human chromosome-1 and/or -2, both in interphase and metaphase spreads. Methods Upon blood collection, dosimetry and irradiation were performed. Lymphocytes were isolated after whole-blood irradiation with 60Co γ-rays in the dose range of 0–5 Gy for both interphase, and metaphase aberration studies. Induction of premature chromosome condensation in interphase cells was accomplished using a phosphatase inhibitor, calyculin-A. Metaphase spreads were harvested from short-term peripheral blood lymphocyte cultures following colcemid arrest and using an automated metaphase harvester and spreader. Aberration analysis in both interphase and metaphase spreads were done using FISH. Results In interphase, aberrant cell and aberration frequency involving chromosome 1 and/or 2 increased linearly with radiation dose. In metaphase, aberrations increased in a linear-quadratic manner with dose. Our studies ascertain that chromosome-2 is more radio-sensitive than chromosome-1 in both interphase and metaphase stages, albeit the DNA content of chromosome-2 is lesser than chromosome-1 by almost 10 million base pairs. Conclusion Differences in radio-sensitivities of chromosomes have implications in genetic damage, chromosome organization, and chromosome function. Designing research experiments based on our vital findings may bring benefit to radiation-induced risk assessment, therapeutics and development of chromosome specific biomarkers.
- Published
- 2009
48. Laboratory Automation for Cytogenetic Biodosimetry and Inter-Laboratory Comparison of the Dicentric Assay
- Author
-
Uma Subramanian, Mitsuaki A. Yoshida, H. Romm, Maria Moroni, K. Krasnopolsky, Ruth C. Wilkins, P.R. Martin, Gordon K. Livingston, and Pataje G. S. Prasanna
- Subjects
Renewable Energy, Sustainability and the Environment ,business.industry ,Health, Toxicology and Mutagenesis ,Public Health, Environmental and Occupational Health ,Chromosome aberration ,Dicentric chromosome ,Nuclear Energy and Engineering ,Biodosimetry ,Radiological weapon ,Laboratory automation ,Dose assessment ,Comparison study ,Medicine ,Inter-laboratory ,Safety, Risk, Reliability and Quality ,Nuclear medicine ,business ,Waste Management and Disposal - Abstract
The dicentric chromosome assay (DCA) is the gold standard biodosimetry method for radiation dose assessment. The DCA can be used for quickly assessing dose to individuals in the early period aftermath of a radiological or nuclear incident for optimum medical aid. DCAs application in radiation mass casualties necessitates greater sample processing and chromosome aberration analysis capacity. Therefore, automated sample processing, chromosome aberration analysis, and establishment of a co-operative network of cytogenetic laboratories are essential. Recent efforts at the Armed Forces Radiobiology Research Institute (AFRRI) focussed on increasing sample processing via automation, technology integration, and implementation of a laboratory information management system (LIMS) for resources and data. We developed a high-throughput, flexible, modular, and scalable robotic blood handling system, which represents a beta version for automated blood handling aiding increased throughput. Other components of the automated cytogenetic biodosimetry laboratory include sample and reagent bar-code tracking, metaphase harvesters and a spreader, slide stainer, a high-throughput metaphase finder, and multiple satellite chromosome-aberration analysis systems all integrated with LIMS. Because use of a cooperative network for chromosome aberration analysis and dose assessment by DCA requires routine quality control exercises among partner laboratories, the National Institute for Allergies and Infectious Diseases (NIAID) and AFRRI sponsored an interlaboratory comparison study to determine DCAs validity and accuracy among five laboratories following the guidelines of International Organization for Standardization.Blood samples irradiated at the AFRRI were shipped to all laboratories, which constructed individual calibration curves in the 0.0- to 5.0-Gy range for 60-Co gamma-rays and assessed the dose to dose-blinded samples. For all laboratories, the estimated coefficients of the fitted curves were within the 99.7% confidence intervals (CIs); but the observed dicentric yields differed. When each laboratory assessed radiation doses to four dose-blinded blood samples by comparing the observed dicentric yield with the laboratorys own calibration curve, the actual doses were within 99.75% CI for the assessed dose. Across the dose range, the error in the estimated doses, compared to the physical doses, was from 15% underestimation to 15% overestimation. Our efforts to improve diagnostic biodosimetry response by the DCA aiding optimum medical treatment for radiation exposed individuals in mass casualties. Acknowledgment: AFRRI and National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, supported this research under Inter Agency Agreement, Y1-AI-5045-04.
- Published
- 2008
49. IR-induced DNA damage is reduced in normal fibroblasts and enhanced in cancer cells by gammatocotrienol
- Author
-
S. Kulkarni, Sanchita P. Ghosh, S. Kumar, Maria Moroni, and Pataje G. S. Prasanna
- Subjects
Cell type ,Renewable Energy, Sustainability and the Environment ,Health, Toxicology and Mutagenesis ,Public Health, Environmental and Occupational Health ,Cancer ,Cell cycle ,medicine.disease_cause ,medicine.disease ,Molecular biology ,chemistry.chemical_compound ,Nuclear Energy and Engineering ,chemistry ,Toxicity ,Cancer cell ,medicine ,Trypan blue ,Safety, Risk, Reliability and Quality ,Clonogenic assay ,Waste Management and Disposal ,Oxidative stress - Abstract
Gamma-tocotrienol (GT3) is an isoform of vitamin E with high anti-oxidant activity. Studies by us have demonstrated that GT3 has low-toxicity and protects mice from lethal irradiation. A study on a limited number of mice has indicated that protective activity of GT3 is selective towards normal tissues, while towards tumors it acts as a radio-sensitizer. The mechanism of selectivity is still unknown. It has been proposed that GT3 accumulates in the tumor as a pro-oxidant quinone and enhances radiation-initiated oxidative stress while in normal cells GT3 act as an anti-oxidant. Oxidative stress from radiation results in DNA-damage and cell death. To study the mechanisms of differential response of GT3 to cancer and normal cells, we used MCF-7 breast cancer cells and AG01522 normal cells incubated in vitro with GT3 and irradiated. Following radiation, these cells were used to determine whether the presence of GT3 reflects in differential levels of DNA-damage. Material and methods: AG01522 normal fibroblasts and MCF-7 breast cancer cells were used for this study. Toxicity and proliferation were measured with the WST-1 assay. Viability was measured with CitoTox-One assay and Trypan Blue exclusion method. γ-H2AX immunostain was used to assess DNA-damage. Irradiation was done using a Co source (2 Gy, 0.6 Gy/min). Survival was determined by clonogenic assay. Results: Most radio-protectors/sensitizers fail in the clinical settings because of their high toxicity. GT3 exhibits levels of toxicity which are cell type dependent. AG01522 were more sensitive to GT3-induced toxicity than MCF-7, but were viable up to 5 ug/ml. Safety of the dose was confirmed by proliferation, viability and cell cycle distribution analysis. To determine radiation-induced DNA-damage in GT3-treated cells, we examined phosphorylation of H2AX (γ-H2AX) at various time points after irradiation by confocal microscopy. γ-H2AX localizes at sites of DNA double-strand-breaks; levels of γ-H2AX and kinetics of removal have been associated with DNA-repair and survival. GT3 reduced the number of γ-H2AX foci in AG01522 and increased the surviving fraction, while it increased DNA-damage and reduced survival in MCF7. Phosphorylation of H2AX was delayed and persistent in GT3-treated MCF-7 cells. Conclusion: In vitro irradiation of GT3-treated normal and cancer cells indicate that GT3 has selective radio-protective/sensitizing roles. Radio-protection of normal cells was associated with reduced DNA-damage, while radio-sensitization of cancer cells was associated with increased DNA-damage and persistent levels of γ-H2AX foci, suggesting a role for GT3 in differential modulation of DNA-repair.
- Published
- 2008
50. Sample Tracking in an Automated Cytogenetic Biodosimetry Laboratory for Radiation Mass Casualties
- Author
-
Pataje G. S. Prasanna, P.R. Martin, Uma Subramanian, William F. Blakely, and R.E. Berdychevski
- Subjects
Radiation ,business.industry ,Sample (material) ,Real-time computing ,Barcode ,Automation ,Chromosome aberration ,Triage ,Article ,law.invention ,Biodosimetry ,law ,Personal computer ,Laboratory automation ,business ,Nuclear medicine ,Instrumentation ,Geology - Abstract
Chromosome aberration-based dicentric assay is expected to be used after mass casualty life-threatening radiation exposures to assess radiation dose to individuals. This will require processing of a large number of samples for individual dose assessment and clinical triage to aid treatment decisions. We have established an automated, high-throughput, cytogenetic biodosimetry laboratory to process a large number of samples for conducting the dicentric assay using peripheral blood from exposed individuals according to internationally accepted laboratory protocols (i.e., within days following radiation exposures). The components of an automated cytogenetic biodosimetry laboratory include blood collection kits for sample shipment, a cell viability analyzer, a robotic liquid handler, an automated metaphase harvester, a metaphase spreader, high-throughput slide stainer and coverslipper, a high-throughput metaphase finder, multiple satellite chromosome-aberration analysis systems, and a computerized sample tracking system. Laboratory automation using commercially available, off-the-shelf technologies, customized technology integration, and implementation of a laboratory information management system (LIMS) for cytogenetic analysis will significantly increase throughput.This paper focuses on our efforts to eliminate data transcription errors, increase efficiency, and maintain samples' positive chain-of-custody by sample tracking during sample processing and data analysis. This sample tracking system represents a "beta" version, which can be modeled elsewhere in a cytogenetic biodosimetry laboratory, and includes a customized LIMS with a central server, personal computer workstations, barcode printers, fixed station and wireless hand-held devices to scan barcodes at various critical steps, and data transmission over a private intra-laboratory computer network. Our studies will improve diagnostic biodosimetry response, aid confirmation of clinical triage, and medical management of radiation exposed individuals.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.